Newsquawk Daily European Equity Opening News - 5th August 2025

ASIA

APAC stocks were mostly higher following the rally on Wall St where the major indices clawed back post-NFP losses amid rate cut hopes. ASX 200 ascended with every sector in the green and outperformance in real estate, tech, and consumer discretionary. Nikkei 225 took impetus from global peers and shrugged off a firmer currency with earnings releases remaining a driver for individual stocks. Hang Seng and Shanghai Comp were ultimately kept afloat after the latest S&P Global PMI figures which showed a strong acceleration in Services PMI, while Composite PMI cooled but remained in expansionary territory.

EUROPEAN CLOSES

CLOSES: Euro Stoxx 50 +1.50% at 5,243, Dax 40 +1.41% at 23,757, FTSE 100 +0.66% at 9,128, CAC 40 +1.14% at 7,632, FTSE MIB +1.89% at 40,697, IBEX 35 +1.76% at 14,375, PSI +1.35% at 7,730, SMI -0.11% at 11,810, AEX +0.44% at 889

SECTORS: Financials 2.01%, Utilities 1.19%, Industrials 1.12%, Telecoms 0.85%, IT 0.51%, Materials 0.31%, Consumer Stpl 0.26%, Consumer Disc 0.17%, Energy 0.12%, Healthcare 0.09%

FTSE 100

UK Motor Finance / Lloyds (LLOY LN) / Close Brothers (CBG LN) - UK FCA head warned UK lenders must stop “haggling” over a planned multibillion-pound redress scheme for consumers mis-sold car finance, according to FT. (FT)

OTHER UK COMPANIES

BROKER MOVES

DAX

Continental (CON GY) - Q2 (EUR): Revenue 9.59bln (exp. 9.67bln, prev. 10bln Y/Y), Adj. EBIT 597mln (exp. 608mln, prev. 711mln Y/Y), Auto segment sales 4.7bln (prev. 5bln Y/Y), Tires segment 3.3bln (prev. 3.4bln Y/Y) Adj. EBIT Margin 6.2% (exp. 7.13%). Listing of the Automotive unit (Aumovio) on the stock exchange planned for Sept. 18, 2025. Outlook: Expects improvements at Tires and Contitech in H2 vs Q2. Affirms FY Revenue guidance but trims Adj. EBIT Margin 10-11% (prev. guided 10.5-11.5%) (Newswires)

DHL (DHL GY) - Q2 (EUR): EBIT 1.43bln (exp. 1.33bln), Revenue 19.8bln (exp. 21bln). Affirms guidance. Still sees FY FCF about EUR 3bln (exp. 2.95bln). Notes that demand surcharge for peak season 2025 is in preparation. Highlights that EUR 1bln has been invested in robotics and automation over the past three years. (Newswires)

Fresenius Medical Care (FME GY) - Q2 (EUR): Revenue 4.79bln (Exp. 4.74bln), EPS 0.91 (prev. 0.72 Y/Y). Affirms outlook. Notes that first tranche of announces share buyback to be initiated in August. (Newswires)

Infineon (IFX GY) - Q3 2025 (EUR): adj. EPS 0.37 (exp. 0.326, prev. 0.43), Revenue 3.7bln (exp. 3.7bln), Profit 305mln (prev. 403mln), Segment Result 668mln (prev. 734mln). Q4 Guidance: Revenue around 3.9bln (exp. 4.06bln). 2025 Guidance: Revenue around 14.6bln (exp. 14.73bln). Adj. Gross Margin at least 40% (prev. guided around 40%) FCF 1.0bln (prev. guided around 0.9bln). Shares -1.9% in pre-market trade ; Weightings: 5.76% in the STOXX 600 Tech sector; 2.17% in the DAX 40; 0.33% in the STOXX 600. ; Note: The press conference begins at 07:00 BST, thereafter, the analyst call will begin at 08:30 BST.

OTHER GERMAN COMPANIES

Aurubis (NDA GY) - 9M (EUR): EBT 286mln (prev. 333mln Y/Y). Outlook 2024/25: Expects EBT to be between 330-370mln (prev. guided 300-400mln). (Newswires)

Hugo Boss (BOSS GY) - Q2 2025 (EUR): Revenue 1.002bln (exp. 0.996bln), EBIT 81mln (exp. 82mln). Q2 Operating expenses are below prior year's level; Co. confirms FY25 outlook; Gross margin remains stable Y/Y. EMEA (Q2: +3%; H1: +1%) and the Americas (Q2: +2%; H1: +1%) return to growth; muted consumer sentiment in China weighs on performance in Asia/Pacific (Q2: –5%; H1: –7%). Outlook: Full-year outlook confirmed: reported Group sales to remain broadly stable (–2% to +2%); EBIT to increase by +5% to +22%, with EBIT margin targeted between 9.0% and 10.0%. Macroeconomic volatility to remain elevated, fuelled by ongoing tariff uncertainty; subdued global consumer sentiment continues to weigh on industry development. Key strategic initiatives to support business performance in H2, including launch of new brand campaigns and BOSS Fashion Show in Milan. Ongoing strong focus on sustainable cost efficiency to drive profitability improvements also in the second half of 2025. Shares +2.9% in pre-market trade

Fraport (FRA GY) - H1 (EUR): EBITDA 561.2mln, -1% Y/Y. Q2: EBITDA 383.7mln, +8.2% Y/Y. Confirms FY guidance. (Newswires)

Gerresheimer (GXI GY) - Co. to separate Moulded Glass and intends to initiate a sale process. (Newswires)

BROKER MOVES

CAC

Technip Energies (TE FP) - Co. awarded major contract for commonwealth LNG export facility in the US. Major award represents above EUR 1bln of revenue. (Newswires)

Vinci (DG FP) - Won a contract for biofuel plant in Spain, estimated at EUR 1.2bln. (Newswires)

OTHER FRENCH COMPANIES

Eutelsat (ETL FP) - FY (EUR): Revenue 1.24bln (exp. 1.22bln), Adj. EBITDA 676mln (exp. 661mln). Guides initial FY26 Revenue "in-line" Y/Y. (Newswires)

BROKER MOVES

PAN EUROPE

Banco BPM (BAMI IM) / Credit Ag (ACA FP) - Credit Ag raised its stake by 0.3% in Banco BPM, taking its total holdings to 20.1%. (Newswires)

EDP (EDPR PL) - Co. signs asset rotation deal for 190 MWac solar portfolio in Spain, for EV of EUR 0.16bln. Transaction closing exp. during 2025. (Newswires)

Naturgy (NTGY SM) - Launches accelerate bookbuild offering and bilateral sale; through this, around 5.5% of share capital will be disposes of. (Newswires)

BROKER MOVES

SMI

Adecco (ADEN SW) - Q2 (EUR): Net Income 58mln (exp. 50.4mln), Adj. EBITA 141mln (exp. 138.8mln), Revenue 5.78bln (prev. 5.84bln Y/Y). GBU Revenue +2% Y/Y. Americas +14% Y/Y, APAC +9% Y/Y. Sees Q3 Gross Margin to rise sequentially in line with seasonality. Expects profitability to improve from H1 levels to H2. CEO notes that the Co. is seeing more movement in defence hiring in Germany than in France. (Newswires)

OTHER SWISS COMPANIES

Alcon (ALCC SW) - Agrees to acquire Staar Surgical (STAA), for USD 28/shr. Transaction is exp. to be accretive to earnings in year two. (Newswires)

Sandoz (SDZ SW) - CEO says they intend to offer generic versions of the semaglutide weight loss drug in Canada once patents begin to expire in 2026, price yet to be determined, but a discount of 60-70% vs the branded version is possible. (FT)

BROKER MOVES

Logitech (LOGN SW) upgraded to Outperform from Neutral at BNP Paribas

SCANDINAVIA

Novo Nordisk (NOVOB DC/NVO) - Co. got notice of unsolicited “mini-tender” offer by TRC Capital to buy up to 2mln ADS's of Co. (Newswires)

BROKER MOVES

US

CLOSES: SPX +1.47% at 6,330 NDX +1.87% at 23,189, DJI +1.34% at 44,174, RUT +2.10% at 2,212.

SECTORS: Energy -0.44%, Consumer Staples +0.42%, Consumer Discretionary +0.68%, Real Estate +0.81%, Financials +0.87%, Industrials +0.91%, Health +1.41%, Materials +1.42%, Utilities +1.74%, Technology +2.15%, Communication Services +2.59%.

Chips - US is exploring better location trackers for AI chips to curtail flows to China, according to Bloomberg. (Bloomberg)

Hims & Hers Health (HIMS) - Shares tumbled by over 15% in extended trading. It reported Q2 EPS of 0.17 (exp. 0.15), Q2 revenue of USD 544.8mln (exp. 551.48mln). GLP-1 revenue fell to USD 190mln (from Q1’s 230mln), as compounded drug subscribers declined; revenue per subscriber dropped to USD 74.00 (from USD 84.00). Said it still expects its FY weight-loss business to contribute USD 725mln in revenue, within its total projected USD 2.5bln in company-wide revenue for 2025. Sees FY Adj. EBITDA USD 295mln-335mln, and sees FY rev. between USD 2.3bln-2.4bln (exp. 2.35bln).

Palantir Technologies (PLTR) - Shares rose 5% in extended trading after its Q2 revenue rose 48% Y/Y, with the company citing “astonishing” AI impact, and it raised its FY revenue outlook again. It reported Q2 adj. EPS of 0.16 (exp. 0.14), Q2 revenue USD 1.00bln (exp. 937.7mln). US government sales were up 53% in the Q2 to USD 426mln. Sees Q3 revenue between USD 1.08-1.09bln (exp. 0.98bln), and sees Q3 adj. income from operations between USD 493-497mln. For the FY25, exec flagged that expenses will rise on hiring, and it sees revenue between USD 4.14-4.15bln (exp. 3.90bln), and adj. income from operations between USD 1.912-1.92bln.

Vertex (VRTX) - Vertex reported Q2 metrics topped expectations, driven by CF drugs and new products, but shares fell over 13% in extended trading after it halted development of a painkiller. Q2 Trikafta sales missed at 2.55bln. It reported Q2 adj. EPS of 4.52 (exp. 4.26), Q2 revenue of USD 2.96bln (exp. 2.92bln). Said David Altshuler will retire as CSO, Mark Bunnage will assume the role. Will not advance VX-993 monotherapy; did not meet the primary endpoint in the study. Reiterated FY25 guidance; FY25 revenue forecast reaffirmed at USD 11.85–12bln; guidance also includes an immaterial cost impact from tariffs in 2025.

05 Aug 2025 - 06:54- EquitiesResearch Sheet- Source: Newsquawk